Coghlan, J. Gerry
Channick, Richard
Chin, Kelly
Di Scala, Lilla
Galiè, Nazzareno
Ghofrani, Hossein-Ardeschir
Hoeper, Marius M.
Lang, Irene M.
McLaughlin, Vallerie
Preiss, Ralph
Rubin, Lewis J.
Simonneau, Gérald
Sitbon, Olivier
Tapson, Victor F.
Gaine, Sean
Clinical trials referenced in this document:
Documents that mention this clinical trial
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
https://doi.org/10.1007/s40256-017-0262-z
Funding for this research was provided by:
Actelion Pharmaceuticals
Article History
First Online: 6 January 2018
Compliance with Ethical Standards
:
: This study was funded by Actelion Pharmaceuticals Ltd (Allschwil, Switzerland). Sally Dempster, Ph.D., and Ruth Lloyd, Ph.D. (nspm Ltd, Meggen, Switzerland) provided medical writing support funded by Actelion Pharmaceuticals Ltd.
: Dr. Channick has served as a steering committee member for Actelion Pharmaceuticals Ltd, has served on an advisory board for Actelion Pharmaceuticals Ltd and Bayer, has received consultancy fees from Bayer, and has received research grants from Actelion Pharmaceuticals Ltd and United Therapeutics. Dr. Chin has served as a steering committee member for Actelion Pharmaceuticals Ltd; has received research grants from Actelion Pharmaceuticals Ltd, Bayer Healthcare, Gilead Sciences Inc., GeNO, NIH, United Therapeutics and SoniVie; and has received consultancy fees from Actelion Pharmaceuticals Ltd and United Therapeutics. Dr. Coghlan has received consultancy fees and honorarium from Actelion Pharmaceuticals Ltd and GlaxoSmithKline, honorarium from Bayer, and congress fees from MSD. Dr. Di Scala is a full-time employee of Actelion Pharmaceuticals Ltd. Professor Gaine has served as a steering committee member for and received research grants from Actelion Pharmaceuticals Ltd; has received speaker fees from Actelion Pharmaceuticals Ltd, Bayer, GlaxoSmithKline, MSD, and United Therapeutics; has received advisory board fees from Actelion Pharmaceuticals Ltd, Bayer, Novartis, Pfizer, and Daiichi-Sankyo; has received travel support from Actelion Pharmaceuticals Ltd, Bayer, GlaxoSmithKline, Novartis, and Daiichi-Sankyo; and has served on a data safety monitoring board for GlaxoSmithKline, Novartis, and United Therapeutics. Prof. Galiè has served as a steering committee member for Actelion Pharmaceuticals Ltd; has received research grants and consultancy fees from Actelion Pharmaceuticals Ltd, Bayer, GlaxoSmithKline, and Pfizer; and has received speaker fees from MSD. Prof. Ghofrani has served as a steering committee member for Actelion Pharmaceuticals Ltd; has received advisory board and speaker fees from Actelion Pharmaceuticals Ltd, Bayer, GlaxoSmithKline, Novartis, and Pfizer; has received consultancy fees from Actelion Pharmaceuticals Ltd, Bayer, Bellerophon Pulse technologies, GlaxoSmithKline, MSD, Novartis, and Pfizer; has received travel support from Actelion Pharmaceuticals Ltd, Bayer, GlaxoSmithKline, MSD, Novartis, and Pfizer; and has received research grants from Actelion Pharmaceuticals Ltd and Deutsche Forschungsgemeinschaft. Prof. Hoeper has served as a steering committee member for Actelion Pharmaceuticals Ltd; has received lecture and consultancy fees from Actelion Pharmaceuticals Ltd, Bayer, GlaxoSmithKline, MSD, and Pfizer; has received consultancy fees from Gilead; and has received research grants from Actelion Pharmaceuticals Ltd. Prof. Lang has served as a steering committee member for Actelion Pharmaceuticals Ltd; has received speaker fees from Actelion Pharmaceuticals Ltd, Bayer, and GlaxoSmithKline; and has received research grants from Actelion Pharmaceuticals Ltd, AOP Orphan Pharmaceuticals, and Bayer. Prof. McLaughlin has received consultancy fees from and served as an advisory board member for Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Bayer, Gilead, Ikaria, and United therapeutics; has served as a steering committee member for Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Bayer, and Gilead; has received personal fees from Steadymed Therapeutics and St Jude Medical; has received travel support from Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Bayer, Gilead, Ikaria, and United Therapeutics; and has received research grants from Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Bayer, Eiger, Gilead, Ikaria, Novartis, and SoniVie Ltd. Dr Preiss is a full-time employee of Actelion Pharmaceuticals Ltd. Prof. Rubin has received grant support from and served as a steering committee member for Actelion Pharmaceuticals Ltd; has received consultancy fees and travel support from Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, GeNO Pharmaceuticals, Gilead, Karos Pharmaceuticals, Pfizer, and SoniVie Ltd; and has three patents issued. Prof. Simonneau has served as a steering committee member for and received research grants from Actelion Pharmaceuticals Ltd and Bayer; has received speaker and consultancy fees from Actelion Pharmaceuticals Ltd, Bayer, GlaxoSmithKline, MSD, and Pfizer. Prof. Sitbon has served as a steering committee member for Actelion Pharmaceuticals Ltd; has served as an advisory board member for and received research grants from Actelion Pharmaceuticals Ltd, Bayer Healthcare, GlaxoSmithKline, and MSD; has received consultancy fees from Actelion Pharmaceuticals Ltd, Bayer Healthcare, GlaxoSmithKline, MSD, and United Therapeutics; has received speaker fees from Actelion Pharmaceuticals Ltd, Bayer Healthcare, GlaxoSmithKline, and United Therapeutics; and has received writing assistance from Actelion Pharmaceuticals Ltd and GlaxoSmithKline. Prof. Tapson has served as a steering committee member for Actelion Pharmaceuticals Ltd, Bayer, and United Therapeutics; has received research grants from Actelion Pharmaceuticals Ltd, Bayer, BIO2 Medical, Daiichi-Sankyo, Inari, Janssen, EKOS/BTG, Arena, Reata, Eiger, and United Therapeutics; has received consulting fees from Actelion Pharmaceuticals Ltd, Bayer, BiO2 Medical, United Therapeutics, Janssen, Arena, Reata, and Vwave medical; and has received lecture honorarium from Actelion, EKOS/BTG, Gilead Sciences, Bayer, and Janssen.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.